XNAS · Healthcare · Biotechnology
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.93 | -0.46 | +50.54% | $0 | ✅ Beat | -2.82% | +2.77% | — |
| 2026-03-27 | Q4 2025 | -0.54 | -0.61 | -12.96% | $0 | ❌ Miss | -0.29% | +1.90% | -0.15% |
| 2025-11-13 |
| Q3 2025 |
| -0.42 |
| -0.48 |
| -14.29% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.48 | -0.35 | +27.08% | $0 | ✅ Beat | -1.40% | -6.66% | +32.77% |
| 2025-03-31 | Q4 2024 | — | -2.23 | — | $0 | — | -8.18% | -20.65% | +14.86% |
| 2024-11-08 | Q3 2024 | -0.48 | -0.37 | +22.92% | $0 | ✅ Beat | -1.30% | +7.17% | +31.99% |
| 2024-08-09 | Q2 2024 | -0.45 | -0.50 | -11.11% | $0 | ❌ Miss | +6.56% | +5.43% | +8.60% |
| 2024-03-28 | Q4 2023 | -0.75 | -0.60 | +20.00% | $0 | ✅ Beat | — | — | — |
Showing last 8 quarters.